| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Marmesinin targets cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2. By inhibiting these enzymes, it can affect the metabolism of various drugs and xenobiotics. It is also an antioxidant, meaning it can scavenge free radicals and protect cells from oxidative stress. Its role as a P450 inhibitor is a key aspect of its biological activity.
|
|---|---|
| ln Vitro |
In vitro, Marmesinin has been characterized as a P450 inhibitor and an antioxidant. Its antioxidant activity can be assessed in cell-free systems by measuring its ability to scavenge free radicals. Its P450 inhibitory activity can be assessed in enzyme assays using recombinant CYP3A4 and CYP1A2 enzymes.
|
| ln Vivo |
In vivo, Marmesinin is a natural product that has been studied for its potential biological effects. Its antioxidant and P450 inhibitory properties suggest it could have a role in modulating drug metabolism and protecting against oxidative stress. However, specific in vivo studies are not detailed in the provided sources.
|
| Enzyme Assay |
In vitro enzyme/receptor binding studies for Marmesinin involve measuring its inhibition of CYP3A4 and CYP1A2. In these assays, the enzyme is incubated with a substrate and varying concentrations of Marmesinin. The inhibition of the enzyme's activity is measured, and the IC50 value is calculated.
|
| Cell Assay |
In vitro cellular assays for Marmesinin are used to study its effects on cells. Its antioxidant activity can be assessed by measuring its ability to reduce oxidative stress in cell cultures. Its P450 inhibitory effects can be studied by measuring the metabolism of a probe substrate in cells expressing these enzymes.
|
| Animal Protocol |
In vivo animal studies for Marmesinin are not detailed in the provided sources. As a natural product, its effects could be studied in models of oxidative stress or drug metabolism.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Marmesinin include its molecular weight of 408.40 g/mol and its formula of C20H24O9. It is a glycoside, which may affect its absorption and metabolism.
|
| Toxicity/Toxicokinetics |
Marmesinin is a natural compound and is generally considered to have a low toxicity profile. As a P450 inhibitor, it has the potential to cause drug-drug interactions. Specific toxicity data are not detailed in the provided sources.
|
| References | |
| Additional Infomation |
Marmesinin is a psoralen compound with the structure (-)-marmesinin, where the hydroxyl hydrogen is replaced by a β-D-glucosyl residue. It is a plant metabolite, a P450 inhibitor, and an antioxidant. It is a β-D-glucosinolate, belonging to the psoralen class of compounds, and is also a monosaccharide derivative. Its function is related to nodakenetin. Ammijin has been reported in Pleurospermum rivulorum, Cnidium monnieri, and other organisms with relevant data.
Marmesinin is a natural furanocoumarin compound. Its CAS number is 495-30-7. It is also known as (-)-Marmesinin. It is a plant metabolite with antioxidant and P450 inhibitory properties. It is a valuable reference standard for analytical and research purposes. |
| Molecular Formula |
C20H24O9
|
|---|---|
| Molecular Weight |
408.39916
|
| Exact Mass |
408.142
|
| CAS # |
495-30-7
|
| PubChem CID |
216283
|
| Appearance |
White to off-white solid powder
|
| Source |
Originated from plants: Compositae Pseudognaphalium affine (D. Don) Anderberg
Originated from plants: Umbelliferae |
| LogP |
0.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
650
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(C)([C@@H]1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O
|
| InChi Key |
HXCGUCZXPFBNRD-NEDVQNLSSA-N
|
| InChi Code |
InChI=1S/C20H24O9/c1-20(2,29-19-18(25)17(24)16(23)13(8-21)28-19)14-6-10-5-9-3-4-15(22)27-11(9)7-12(10)26-14/h3-5,7,13-14,16-19,21,23-25H,6,8H2,1-2H3/t13-,14+,16-,17+,18-,19+/m1/s1
|
| Chemical Name |
(2S)-2-[2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~122.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4486 mL | 12.2429 mL | 24.4858 mL | |
| 5 mM | 0.4897 mL | 2.4486 mL | 4.8972 mL | |
| 10 mM | 0.2449 mL | 1.2243 mL | 2.4486 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
